Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Menlo College
Redwood City, California, United Statesmenloathletics.com ↗
- Ownership
- Private
- Employees
- ~3
- Development stage
- Other
01
Overview
VYNE Therapeutics, formerly Menlo Therapeutics, has developed and commercialized two FDA-approved topical minocycline foams—AMZEEQ for acne vulgaris and ZILXI for rosacea. The company also advanced serlopitant, an oral small molecule NK1R antagonist for pruritus. Their proprietary Molecule Stabilizing Technology underpins their dermatology product portfolio.
- Therapeutic areas
- Dermatology
- Modalities
- Small moleculeTopical foam formulationBiologic
- Industry
- Academic Hospital/University/Research
Beyond the preview
Go deeper on Menlo College.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Menlo College.